Business Wire

SoftServe Offers Complimentary Assessment for In-Store Social Distancing Solution

28.7.2020 14:00:00 EEST | Business Wire | Press release

Share

SoftServe, a leading digital authority and consulting company, is offering a complimentary assessment through September 30, 2020 for its In-Store Social Distancing Solution, a cloud-based computer vision and mobile app solution that offers retailers a 360-degree customer view through AI-powered advanced analytics to support value-led decision making through actionable insights. This solution enables stores to provide a secure shopping environment for customers and employees while remaining compliant with government mandated social distancing regulations, as well as track customer engagement to understand future buying dynamics and optimize store layouts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005019/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoftServe's In-Store Social Distancing Solution mobile interface. (Photo: Business Wire)

Computer vision is a form of artificial intelligence (AI) that trains computers to interpret and understand digital images from cameras and videos. Computers can ‘learn’ to accurately identify and classify objects, and then react to and report on what they ‘see’. It’s a rapidly growing platform for real-time store management and enhanced operations. By 2021, 40% of retailers will implement computer vision in their customer service and support workflow, and vendors employing computer vision in retail will see a 20% lift in conversion.1

“SoftServe’s in-store social distancing solution is bridging a critical gap for retailers, ensuring a safe shopping environment through the COVID-19 pandemic while providing a valuable long-term solution for continual security, future growth, and consumer engagement,” said Valentyn Kropov, VP, client success at SoftServe. “Our solution works with your existing in-store equipment and can be ‘retrained’ around future scenarios, giving you a foundation on which to optimize store operations and customer experience for years to come.”

Ensure Customer and Employee Safety and Social Distancing Regulatory Compliance

  • Mask and Temperature Detection—detect if patrons are wearing masks and scan customers’ temperatures with an infrared thermometer upon entry.
  • Manage Store Capacity—count the number of patrons entering and exiting the store and provide entry permission alerts and QR code vouchers through a mobile app.
  • Avoid Physical Lines—track designated distance between queued customers, provide department wait times and information through digital signage, and allow patrons to reserve spots in line.

Identify and Understand Customers’ Buying Dynamics

  • Real-Time Data Processing—get actionable insights in the moment with a self-learning system that fully automates data collection.
  • In-Store Customer Tracking—understand your customers’ in-store movements and product engagement better with demographics and heatmap analysis.
  • Create More Immersive Shopping Experiences—learn customer interaction points and deploy AI-driven dynamic in-store advertisements. Use location analytics to optimize store layout and product positioning around customer preferences.

SoftServe’s In-Store Social Distancing Solution integrates with a store’s existing CCTV infrastructure and software platforms and can be rapidly deployed to be up and running in a couple of weeks. It’s designed to be scalable for hundreds of stores, yet is customizable around the specific business needs of each individual store.

Book your complimentary assessment and demo through the end of September today. Contact RetailDemo@softserveinc.com for a timely evaluation of your store environment to identify the most cost-efficient solution.

1 Nick Ingelbrecht, Anthony Bradley “Emerging Technologies: Top Advanced Computer Vision Use Cases for Retail”, Gartner, April 23, 2020

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.

SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.

Visit our website, blog, LinkedIn, Facebook, and Twitter pages.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye